Try our Advanced Search for more refined results

IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION

Track this case

Case Number:

9:20-md-02924

Court:

Florida Southern

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation, Class Action

Judge:

Robin L. Rosenberg

Firms

Companies

Sectors & Industries:

  1. January 19, 2022

    Drugmakers Want Discovery From Valisure In Zantac MDL

    GlaxoSmithKline LLC urged a Florida magistrate judge on Wednesday to allow it to get more information from pharmacy Valisure LLC in multidistrict litigation over alleged links between the heartburn drug Zantac and various cancers, arguing that Valisure's initial testing of the drug and citizen petition to the U.S. Food and Drug Administration "permeates through the case."

  2. October 25, 2021

    Parties In Zantac MDL Propose Path To 2023 Bellwether Trials

    The parties in sprawling multidistrict litigation over alleged links between the heartburn drug Zantac and various cancers presented a joint plan Monday for narrowing a field of more than 130,000 potential personal injury claimants to serve as plaintiffs in initial bellwether trials targeted for 2023.​​​​​​​

  3. October 07, 2021

    Drug Cos. Can't Nix Monitoring Class In Zantac MDL

    A Florida federal judge won't let drugmakers escape claims from a class alleging that their use of Zantac and its generics have given them an increased risk of cancer, saying the class members don't need to specify their particular level of exposure to carcinogens to keep their suit afloat.

  4. October 04, 2021

    Drugmakers In Zantac MDL Try To Trim Claims

    Drugmakers targeted in multidistrict litigation over a carcinogen found in heartburn medication Zantac urged a Florida federal court Monday to toss medical monitoring claims, arguing that the plaintiffs have failed again to specify levels of the carcinogen that would cause an increased cancer risk.

  5. August 24, 2021

    Zantac Makers, Retailers Urge Nix Of Medical Monitoring Class

    Manufacturers and retailers of the heartburn medication Zantac urged a Florida federal judge on Monday to dismiss the medical monitoring claims of a class of consumers in multidistrict litigation because they had failed to show that their exposure to the carcinogen in the drug was enough to increase their risk of cancer.

  6. July 09, 2021

    Generics, Retailers Escape Zantac MDL With Preemption

    A Florida federal judge dismissed all claims against manufacturers of the generic form of the heartburn medication Zantac and retailers in sprawling multidistrict litigation alleging the drug contains a known carcinogen, finding that all claims are preempted by federal law.

  7. July 01, 2021

    Retailers, Pharmacies Freed From Zantac Personal Injury MDL

    A Florida federal judge on Wednesday cut loose retailers and pharmacies from multidistrict litigation over the heartburn medication Zantac, ruling that consumers' claims that the companies' negligence played a part in a carcinogen forming in the drug were implausibly claimed. 

  8. June 04, 2021

    Retailers, Generics Makers Want Out Of Zantac MDL

    Retailers and generics manufacturers asked a Florida federal court Friday to let them exit a multidistrict litigation over heartburn medication Zantac, arguing they're the wrong targets for the claims regarding a carcinogen found in the drug.

  9. June 03, 2021

    Drugmakers Urge Fla. Court To Trim Zantac MDL

    Consumers suing drugmakers and others in a multidistrict litigation over a carcinogen found in heartburn medication Zantac fought Thursday in Florida federal court to keep their claims alive as the defendants argued their claims lacked specificity or an actual injury.

  10. January 11, 2021

    Name Brand Drug Cos. Ax Labeling Claims In Zantac MDL

    A Florida federal judge presiding over sprawling multidistrict litigation involving the carcinogens found in the heartburn medication Zantac cut more claims on Friday from the litigation, holding that design defect claims are barred by federal law.